Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The employee options vest over four years, subject to continued service, and have a ten-year term.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sagimet Biosciences (SGMT) granted 63,600 stock options to two newly hired employees on October 28, 2026, as employment inducements. The awards cover Series A common stock under the Nasdaq Rule 5635(c)(4) exception. Their exercise price equals the stock’s closing price on the Nasdaq Global Market that day.
The options have a ten-year term and vest over four years, subject to continued service. Management will also participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026, at 10:30am ET.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.63,600 stock options granted to two new employees create potential dilution upon exercise.
Details
News Market Reaction – SGMT
On Oct 29, the day this news came out, SGMT closed 2.89% below the previous close. Our momentum scanner recorded 7 alerts for this stock that day.
Data tracked by StockTitan Argus for the Oct 29 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here).
Inducement Grant
In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 63,600 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on October 28, 2026 to the newly hired employees.
The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to the acceptance of employment with Sagimet.
The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on October 28, 2026. The options have a ten-year term and vest over four years, with
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company advancing a portfolio of novel fatty acid synthase (FASN) inhibitors. FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can cause elevated sebum and inflammation. FASN is also implicated in other diseases, including MASH and certain FASN-dependent tumor types. Denifanstat, Sagimet’s lead drug candidate, is an oral, once-daily FASN inhibitor currently being evaluated in a U.S. Phase 3 registrational clinical trial for moderate to severe acne. For more information, visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Sagimet’s October 2026 employee stock option grants?
Sagimet granted 63,600 stock options in aggregate to two newly hired employees on October 28, 2026. The exercise price equals the Series A common stock’s closing price on the Nasdaq Global Market that day. The options have a ten-year term and vest over four years, subject to continued service.
How do Sagimet’s October 2026 inducement options vest?
25% of the shares underlying each option vest on the one-year anniversary of the applicable vesting commencement date, based on the employee’s employment commencement date. The remaining shares vest monthly over 36 months thereafter, subject to continued service through each applicable vesting date.